Menu
← Oncology Approval Tracker
FDA DECISION ·
Jemperli + carboplatin + paclitaxel
dostarlimab-gxly + carboplatin + paclitaxel · GlaxoSmithKline
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For primary advanced or recurrent endometrial cancer with dMMR or MSI-H. Start with carboplatin and paclitaxel plus dostarlimab, then continue dostarlimab alone.
LAMPGEN ANALYSIS
Why it matters
This added immunotherapy to chemotherapy for a biomarker-selected advanced or recurrent population.
What research teams should watch
Document mismatch repair or MSI testing and the transition from combination to maintenance therapy.
PRIMARY RECORDS